BOXER CAPITAL LLC
Q2 2024 Form 13-F
SAN DIEGO, CALIFORNIA
CIK 0001465837
· CRD 330106
· SEC-registered investment adviser
$1.9B Reported Value Total
BOXER CAPITAL MANAGEMENT, LLC reports 1 total accounts under management (AUM). There are 1 discretionary accounts valued at $2,543,913,691, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
2 funds
· $578.2M gross asset value
Hedge Fund: $578.2M
Source: Form ADV filed 2026-05-11
Reported value
$1.9B
Quarter over quarter
-9.3%
Holdings
61
Top-10 concentration
54.3%
Filing Structure
Reports holdings for
- Aviva Holdings Ltd. (not a 13F filer in our records) · File #28-17342 · Q1 2016 – Q3 2017 · declared by one filing
- Aviva Holdings Ltd. (not a 13F filer in our records) · Q4 2015 – Q4 2015 · declared by one filing
Key People
Form ADV owners & control persons
LLC Boxer Holdings Gp
MANAGER
Aaron Isaac Davis
MANAGER AND MEMBER
Tiffany Ann Ayres
CHIEF COMPLIANCE OFFICER AND LEGAL COUNSEL
Filing Navigation
13F Metrics
Loading 13F Metrics
Q2 2024 13F record
Q2 2024 13F filing summary
| Period of report | June 30, 2024 |
|---|---|
| Filed | August 14, 2024 |
| Form | 13F-HR |
| Reported value | $1.9B |
| Positions | 61 |
| Change in reported value | -6.2% |
| New positions | 4 |
| Exited positions | 2 |
| Position turnover | 9.5% |
| Top-10 concentration | 54.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q4 2024 13F
Filed Feb 14, 2025
|
0 | $0 |
|
Q3 2024 13F
Filed Nov 14, 2024
|
68 | $2.0B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
61 | $1.9B |
|
Q1 2024 13F
Filed May 15, 2024
|
59 | $2.0B |
|
Q4 2023 13F
Filed Feb 14, 2024
|
52 | $2.0B |
|
Q3 2023 13F
Filed Nov 14, 2023
|
73 | $1.9B |
|
Q2 2023 13F
Filed Aug 14, 2023
|
79 | $2.2B |
|
Q1 2023 13F
Filed May 15, 2023
|
75 | $2.0B |
|
Q4 2022 13F
Filed Feb 14, 2023
|
71 | $1.9B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
73 | $1.8B |
|
Q2 2022 13F
Filed Aug 15, 2022
|
76 | $1.6B |
|
Q1 2022 13F
Filed May 16, 2022
|
74 | $1.9B |
|
Q4 2021 13F
Filed Feb 14, 2022
|
70 | $2.6B |
|
Q3 2021 13F
Filed Nov 15, 2021
|
87 | $2.9B |
|
Q2 2021 13F
Filed Aug 16, 2021
|
95 | $2.8B |
|
Q1 2021 13F
Filed May 17, 2021
|
85 | $2.9B |
|
Q4 2020 13F
Filed Feb 16, 2021
|
78 | $3.1B |
|
Q3 2020 13F
Filed Nov 16, 2020
|
75 | $2.9B |
|
Q2 2020 13F
Filed Aug 14, 2020
|
65 | $2.3B |
|
Q1 2020 13F
Filed May 15, 2020
|
61 | $1.5B |
17 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q2 2024
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | RVMD Revolution Medicines Inc | $166.1M | 8.75% |
| 2 | SWTX Springworks Therapeutics Inc | $128.9M | 6.79% |
| 3 | CYTK Cytokinetics Inc | $113.8M | 5.99% |
| 4 | MRUS Merus N V | $112.4M | 5.92% |
| 5 | TYRA Tyra Biosciences Inc | $103.1M | 5.43% |
| 6 | SRPT Sarepta Therapeutics Inc | $102.7M | 5.41% |
| 7 | NUVL Nuvalent Inc | $85.0M | 4.48% |
| 8 | IDYA Ideaya Biosciences Inc | $77.3M | 4.07% |
| 9 | ONC BeiGene Ltd | $71.3M | 3.76% |
| 10 | RNA Avidity Biosciences Inc | $70.6M | 3.72% |
| 11 | TNGX Tango Therapeutics Inc | $70.3M | 3.7% |
| 12 | APLS Apellis Pharmaceuticals Inc | $66.2M | 3.49% |
| 13 | ITOS iTeos Therapeutics Inc | $43.7M | 2.3% |
| 14 | ARGX Argenx SE | $43.0M | 2.26% |
| 15 | AKRO Akero Therapeutics Inc | $39.3M | 2.07% |
| 16 | NKTX Nkarta Inc | $33.1M | 1.75% |
| 17 | ANAB AnaptysBio Inc | $32.6M | 1.72% |
| 18 | AXSM Axsome Therapeutics Inc | $32.2M | 1.7% |
| 19 | RCKT Rocket Pharmaceuticals Inc | $31.6M | 1.66% |
| 20 | FATE Fate Therapeutics Inc | $26.9M | 1.42% |
Values as reported on the Q2 2024 Form 13F. Every position is in the holdings table below.